Best Practice & Research Clinical Rheumatology
Volume 20, Issue 4 , Pages 695-706 , August 2006

Osteoporotic fractures in older adults

  • Cathleen S. Colón-Emeric

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC 27710, USA. Tel.: +1 919 660 7517; Fax: +1 919 684 8569.

References 

  1. US Department of Health and Human Services . Bone Health and Osteoporosis: a Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004;
  2. Cooper C, Campion G, Melton L. Hip fractures in the elderly: a world-wide projection. Osteoporosis International. 1992;2:285–289
  3. Cooper C, Melton L. Epidemiology of osteoporosis. Trends in Endocrinology and Metabolism. 1992;3:224–229
  4. Diamond T, Thornley S, Sekel R, Smerdely P. Hip fracture in elderly men: prognostic factors and outcomes. The Medical Journal of Australia. 1997;167:412–415
  5. Ray N, Chan J, Thamer M, Melton L. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. Journal of Bone and Mineral Research. 1997;12:24–35
  6. Zimmerman S, Chandler J, Hawkes W, et al. Effect of fracture on the health care use of nursing home residents. Archives of Internal Medicine. 2002;162:1502–1508
  7. Salkeld G, Cameron I, Cumming R, et al. Quality of life related to fear of falling and hip fracture in older women. A time trade off study. BMJ. 2000;320:341–346
  8. Lyles K, Gold D, Shipp K, et al. Association of osteoporotic vertebral compression fractures with impaired functional status. The American Journal of Medicine. 1993;94:595–601
  9. Fox K, Hawkes W, Hebel J, et al. Mobility after hip fracture predicts health outcomes. Journal of the American Geriatrics Society. 1998;46:169–173
  10. Crans G, Silverman S, Genant H, et al. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis and Rheumatism. 2004;50:4028–4034
  11. Picavet H, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Annals of the Rheumatic Diseases. 2004;63:723–729
  12. Handoll H, Farrar M, McBirnie J, et al. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database of Systematic Reviews. 2002;4:CD000305
  13. Britt S, Barker D, Maxwell R, et al. The impact of pelvic and lower extremity fractures on the incidence of lower extremity deep vein thrombosis in high-risk trauma patients. The American Surgeon. 2003;69:459–463
  14. Turpie A, Bauer K, Eriksson B, Lassen M. Fondaparinux vs enoxaparin for the prevention of venous thromboemolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Archives of Internal Medicine. 2002;162:1833–1840
  15. PEP Trial Collaborative Group . Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention Trial. Lancet. 2000;355:1295–1302
  16. Eriksson B, Lassen M, Colwell CJ. Efficacy of fondaparinux for thromboprophylaxis in hip fracture patients. The Journal of Arthroplasty. 2004;19(supplement 2):78–81
  17. Francis J. Delirium in older patients. Journal of the American Geriatrics Society. 1992;40:829–838
  18. Brauer C, Morrison R, Silberzweig S, Siu A. The cause of delirium in patients with hip fracture. Archives of Internal Medicine. 2000;160:1856–1860
  19. Marcantonio E, Flacker J, Wright R, Resnick N. Reducing delirium after hip fracture: a randomized trial. Journal of the American Geriatrics Society. 2001;49:516–522
  20. Edelstein D, Aharonoff G, Karp A, et al. Effect of postoperative delirium on outcome after hip fracture. Clinical Orthopaedics and Related Research. 2004;422:195–200
  21. Morrison R, Siu A. A comparison of pain and its treatment in advanced dementia and cognitively intact patients with hip fracture. Journal of Pain and Symptom Management. 2000;19:240–248
  22. Morrison R, Magaziner J, Gilbert M, et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. The Journals of Gerontology. Series A. 2003;58:76–81
  23. Fink J, Ensrud K, Nelson D, et al. Disability after clinical fracture in postmenopausal women with low bone density: the Fracture Intervention Trial (FIT). Osteoporosis International. 2003;14:69–76
  24. Handoll H, Sherrington C, Parker M. Mobilisation strategies after hip fracture surgery in adults. Cochrane Database of Systematic Reviews. 2004;4:CD001704
  25. Penrod J, Boockvar KL, Litke A, et al. Physical therapy and mobility 2 and 6 months after hip fracture. Journal of the American Geriatrics Society. 2004;52:1114–1120
  26. Hodgson S, Mawson S, Stanley D. Rehabilitation after two-part fractures of the neck of the humerus. The Journal of Bone and Joint Surgery. 2003;85:419–422
  27. Liow R, Cregan A, Nanda R, Montgomery R. Early mobilisation for minimally displaced radial head fractures is desirable. A prospective randomized study of two protocols. Injury. 2002;33:801–806
  28. Binder E, Brown M, Sincacore D, et al. Effects of extended outpatient rehabilitation after hip fracture: a randomized controlled trial. JAMA. 2004;292:837–846
  29. Tinetti M, Baker D, Gottschalk M, et al. Home-based multicomponent rehabilitation program for older persons after hip fracture: a randomized trial. Archives of Physical Medicine and Rehabilitation. 1999;80:916–922
  30. Gold D, Shipp K, Pieper C, et al. Group treatment improves trunk strength and psychological status in older women with vertebral fractures: results of a randomized clinical trial. Journal of the American Geriatrics Society. 2004;52:1471–1478
  31. Papaioannou A, Adachi J, Winegard K, et al. Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporosis International. 2003;14:677–682
  32. Diamond T, Champion B, Clark W. Management of acute osteoporotic vertebral fractures: a nonrandomized trial comparing percutaneous vertebroplasty with conservative therapy. The American Journal of Medicine. 2003;114:257–265
  33. Laredo J, Hamze B. Complications of percutaneous vertebroplasty and their prevention. Skeletal Radiology. 2004;33:493–505
  34. Fribourg D, Tang C, Sra P, et al. Incidence of subsequent vertebral fracture after kyphoplasty. Spine. 2004;29:2270–2276
  35. Uppin A, Hirsch J, Centenera L, et al. Occurrence of new vertebral body fracture after percutaneous vertebroplasty in patients with osteoporosis. Radiologia. 2003;226:119–124
  36. Nelson H, Morris C, Kraemer D, et al. Osteoporosis in Postmenopausal Women: Diagnosis and Monitoring. Rockville, MD: Agency for Healthcare Policy and Research; 2002;
  37. Kelepouris N, Harper K, Gannon F, et al. Severe osteoporosis in men. Annals of Internal Medicine. 1995;123:452–460
  38. Thomas M, Lloyd-Jones D, Thadhanai R, et al. Hypovitaminosis D in medical inpatients. The New England Journal of Medicine. 1998;3338:777–783
  39. Semba R, Garrett E, Johnson B, et al. Vitamin D deficiency among older women with and without disability. The American Journal of Clinical Nutrition. 2000;72:1529–1534
  40. Bischoff-Ferrari H, Dawson-Hughes B, Willet W, et al. Effect of vitamin D on falls: a meta-analysis. JAMA. 2004;291:1999–2006
  41. Steingrimsdottir LG, Indridason O, Franzson L, Sigurdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA. 2005;294:2336–2341
  42. Tangpricha V, Pearce E, Chen T, Holick M. Vitamin D insufficiency among free-living healthy young adults. The American Journal of Medicine. 2002;112:659–662
  43. Rosen C, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. The New England Journal of Medicine. 2003;348:1503–1504
  44. Fox K, Magaziner J, Hawkes W, et al. Loss of bone density and lean body mass after hip fracture. Osteoporosis International. 2000;11:31–35
  45. Klotzbuecher C, Ross P, Landsman P, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical analysis. Journal of Bone and Mineral Research. 2000;15:721–739
  46. Colon-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporosis International. 2003;14:879–883
  47. Torgerson D, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Annals of the Rheumatic Diseases. 1998;57:378–379
  48. Colon-Emeric C, Yballe L, Sloane R, et al. Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic fracture. Journal of the American Geriatrics Society. 2000;48:1261–1263
  49. Chapuy M, Arlot M, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. The New England Journal of Medicine. 1992;327:1637–1642
  50. Dawson-Hughes B, Harris S, Krall E, Dallal G. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. The New England Journal of Medicine. 1997;337:670–676
  51. Chestnut C, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal women. Journal of Bone and Mineral Research. 2004;19:1241–1249
  52. Cranney A, Waldegger L, Zytaruk N, et al. Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database of Systematic Reviews. 2003;4:CD004523
  53. Bone H, Hosking DD, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. The New England Journal of Medicine. 2004;350:1189–1199
  54. Greenspan S, Schneider D, McClung M, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Archives of Internal Medicine. 2002;136:742–746
  55. Boonen S, McClung M, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. Journal of the American Geriatrics Society. 2004;52:1832–1839
  56. Colon-Emeric C, Caminis J, Suh T, et al. The HORIZON recurrent fracture trial: design of a clinical trial in the prevention of subsequent fractures after low-trauma hip fracture repair. Current Medical Research and Opinion. 2004;20:903–910
  57. Adolphson P, Abbaszadegan H, Boden H, et al. Clodronate increases mineralization of callus after Colles' fracture: a randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthopaedica Scandinavica. 2000;71:195–200
  58. Fleisch H. Can bisphosphonates be given to patients with fractures?. Journal of Bone and Mineral Research. 2001;16:437–440
  59. Jachna C, Shireman T, Whittle J, et al. Differing patterns of antiresorptive pharmacotherapy among nursing facility residents and community dwellers. Journal of the American Geriatrics Society. 2005;53:
  60. Chestnut C, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. The American Journal of Medicine. 2000;109:267–276
  61. Mehta N, Malootian A, Gilligan J. Calcitonin for osteoporosis and bone pain. Current Pharmaceutical Design. 2003;9:2659–2676
  62. Neer R, Arnaud C, Zanchetta J, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. The New England Journal of Medicine. 2001;344:1434–1441
  63. Finkelstein J, Hayes A, Hunzelman J, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. The New England Journal of Medicine. 2003;349:1216–1226
  64. Black D, Bilezikian J, Ensrud K, et al. One year of alendronate after one year of parathyroid hormone. The New England Journal of Medicine. 2005;353:555–565
  65. Ettinger B, Black D, Mitlak B, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637–645
  66. Barret-Connor E, Cauley J, Kulkarni P, et al. Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Journal of Bone and Mineral Research. 2004;19:1270–1275
  67. Kannus P, Parkkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. The New England Journal of Medicine. 2000;343:1506–1513
  68. Parker M, Gillespie W, Gillespie L. Hip protectors for preventing hip fractures in older people. Cochrane Database of Systematic Reviews. 2005;3:
  69. Kannus P, Parkkari J, Poutala J. Comparison of force attenuation properties of four different hip protectors under simulated falling conditions in the elderly: an in vitro biomechanical study. Bone. 1999;25:229–235
  70. Colon-Emeric C, Datta S, Matchar D. An economic analysis of external hip protector use in ambulatory nursing facility residents. Age and Ageing. 2003;32:47–52
  71. Tinetti M. Preventing falls in elderly persons. The New England Journal of Medicine. 2003;348:42–49
  72. Gillespie L, Gillespie W, Robertson M, et al. Interventions for preventing falls in elderly people. Cochrane Database of Systematic Reviews. 2004;
  73. Ray W, Taylor J, Meador K, et al. A randomized trial of a consultation service to reduce falls in nursing homes. JAMA. 1997;278:557–562

PII: S1521-6942(06)00045-3

doi: 10.1016/j.berh.2006.04.004

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 4 , Pages 695-706 , August 2006

Article Tools